amiloride (Midamor, Amipramidin, Modamide)

Introduction

Tradename: Midamor.

Indications

• lithium-induced nephrogenic diabetes insipidus
• hypercalcemia
• hypokalemia
• hypertension
• edema

Dosage

5-10 mg PO QD

Tabs: 5 mg.

Dosage adjustment in renal failure

• lower dose with eGFR < 30 mL/min

Adverse effects

• hyperkalemia, hyponatremia

• drug adverse effects of diuretics
• drug adverse effects of antihypertensive agents

Drug interactions

• hyperkalemia potentiated by concomitant use of ACE inhibitors, NSAIDs, diabetes.

• drug interaction(s) SGLT2 inhibitors (flozins) with diuretics
• drug interaction(s) of diuretics in combination with Zn+2
• drug interaction(s) of antiarrhythmic agents in combination with diuretics
• drug interaction(s) of calcium channel blockers with diuretics
• drug interaction(s) of spironolactone with potassium-sparing diuretics
• drug interaction(s) of ACE inhibitors with potassium-sparing diuretics
• drug interaction(s) of diuretics with angiotensin II receptor antagonists
• drug interaction(s) of diuretics with ACE inhibitors
• drug interaction(s) of NSAIDs, diuretics & angiotensin II receptor antagonists
• drug interaction(s) of NSAIDs, diuretics & ACE inhibitors
• drug interaction(s) of NSAIDs & antihypertensives

Mechanism of action

• inhibits collecting duct lumenal Na+ channel
• blocks uptake of Li+ by the distal tubule & collecting duct
• mild extracellular fluid volume contraction
• increased Na+ & H2O absorption at the proximal tubule
• decreased urine volume

More general terms

• K+ sparing diuretic

Component of

• amiloride/furosemide
• amiloride/hydrochlorothiazide; amiloride/HCTZ (Moduretic)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16231
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=68540
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16230
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=657389